AbstraCt. The National Cooperative Gallstone Study was a double-masked trial conducted to determine the efficacy and safety of chenodeoxycholic acid (chenodiol) April 1984April , 1156April -1166 patients at base line and after 3-mo therapy, on 45% at 12 mo, and on 36% at 24 mo. Among these specimens, 20% were inadequate for analysis. For analysis of data, available values during therapy were averaged up to time of dissolution, study exit, or study termination. In the high-dose group, percent chenodiol (molar percent of all bile acids) increased markedly and remained high during the 2 yr of follow-up. Also, molar percent cholesterol decreased significantly and remained low during the 2 yr of follow-up. In the low-dose group, percent chenodiol increased and remained significantly increased. Percent cholesterol saturation decreased at 3 mo, but at 24 mo it was not different from that in the placebo group, suggesting a physiological adaptation to the low dose by 2 yr.
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79% of patients on high dose had greater than 70% chenodiol. Among these, half showed unsaturated bile (<100% cholesterol saturation) while the remainder were supersaturated; in the former group with unsaturated bile, 23% had complete dissolution and 51% had partial (>50% reduction in stone size) or complete dissolution. In contrast, those with over 70% chenodiol and supersaturated bile had only 5% complete dissolution. Thus, development of unsaturated bile was a major factor associated with 
Introduction
Several studies have shown that oral administration of the primary bile acid chenodiol (chenodeoxycholic acid) will dissolve cholesterol gallstones in some patients (1) (2) (3) (4) (5) (6) (7) (8) . The probable mechanism of dissolution is to decrease the saturation of bile with respect to cholesterol (9) . Recently, the results of a large clinical trial of chenodiol for dissolution of gallstones, the National Cooperative Gallstone Study (NCGS)', were reported (10) (11) (12) (13) (14) (15) . This trial evaluated the efficacy and safety of two doses of chenodiol (750 and 375 mg/d) in patients with radiolucent gallstones. Among 305 patients who were randomly assigned to receive the high dose for 2 yr, confirmed complete dissolution occurred in 14% of patients; partial (over 50%) or complete dissolution were observed in 41%. In 306 patients on the low dose, partial or complete dissolution occurred in 24%, but complete dissolution in only 5%. Of the remaining 305 patients who received placebo, only 10% and 1% had partial and complete dissolution, respectively. Dissolution was more common in women, thin patients, those with small or floating gallstones, and patients with high serum cholesterol within the normal range. A substantial portion of the patients in this trial underwent duodenal intubation for collection of gallbladder bile at base line and during the study. Bile specimens were analyzed in a Central Bile Laboratory for biliary lipid composition and for individual bile acids. The purpose ofthis report is to summarize the results of these analyses; particular attention will be given to the effects of chenodiol administration on biliary lipid composition and dissolution of radiolucent gallstones.
Methods
Study design. The and any follow-up visit. These patients (37% of total NCGS population) constitute the study sample for this paper. This percentage dropped to 29% at months 3 and 12, and to 24% at month 24.
Characteristics of the biliary lipid study sample were compared with all white patients of the NCGS. The few factors on which they differed are presented in Table II . The characteristics of the total study group were presented previously (10) .
Laboratory methods. Bile samples were collected at the Treatment Centers, and the specimens were then stored in a refrigerator until shipment to the Central Bile Laboratory at the Veterans Administration Medical Center, San Diego, CA. In a previous report on pretreatment biliary lipid composition (12) , detailed laboratory procedures were described for collection of bile samples, analysis of bile for lipids and individual bile acids, calculation ofpercentage saturation, collection and analysis of serum lipids and liver tests, and quality control of serum and bile analysis. All of these procedures were used in the present study.
When the bile acids contained >2% lithocholic acid by gas-liquid chromatography (GLC), the fraction of lithocholic present as its sulfate was measured. The sulfated and unsulfated bile acids, along with internal radioactive recovery standards, were first separated on columns of Se- markedly increased percent chenodiol in both high-dose and low-dose groups; however, the increase was significantly greater in the high-dose than in the low-dose group. The increase in percent chenodiol was slightly greater in females than in males in both dosage groups. Although there appeared to be a slight drop in percent chenodiol at month 24 at both dose levels in men and women, the high percentages of chenodiol generally were maintained throughout the study. The percent chenodiol in the placebo group was unchanged. Reciprocal changes were noted for both percentage of cholic acid and deoxycholic acid in all patients of both groups. Percentage of ursodeoxycholic acid appeared to be increased slightly during chenodiol feeding in men, whereas the differences between the groups were not significant; for women, the percentage of ursodeoxycholic acid was significantly increased in the treatment groups above that for placebo at months 3 and 12 (but not month 24). The high-dose group had a significant increase in percent lithocholic acid for men at all time points; for women, the increase was significant only at month 24 . On low dose, men did not have a significant increase in percent lithocholic acid, and women had a significant increase only at month 24. Mean levels for biliary lipids, adjusted for base-line values, are shown for men in Fig. 3 and for women in Fig. 4 . For both sexes, percent cholesterol saturation fell markedly in the highdose group, and remained low throughout the study. The reduction in percent saturation was paralleled closely by a fall in molar percent cholesterol.
For men in the low-dose group, percent saturation was reduced as much in the high-dose group over the first 3 mo, but at month 24 saturation rebounded back to levels approaching those of the placebo group. Women on low dose showed a somewhat less reduction in saturation in the first 3 mo, and the same rebound at month 24 also was noted. Thus, low-dose chenodiol appeared to lose its effectiveness in both sexes by month 24. As described for the major trial (10) , among all patients, on average 92% of the intended dosage was actually received and these fluctuations in biliary lipids could not be explained by a progressive reduction in adherence. The same results were observed in analyses adjusting for fluctuations in body weight, and in analyses among the cohort of patients actually followed for 24 mo. Thus, the rebound in the low-dose group also was not influenced by weight change or the exit of patients from the study. For the placebo group, no consistent change in bile saturation was noted throughout the study in either men or women.
Correlations among biliary measures. Follow-up values for molar percent chenodiol at 12 and 24 mo were not correlated with base-line values in the high-dose group, but they were correlated highly with previous follow-up values (Table III) The slopes of percent chenodiol in bile versus total body weight in the high-dose group are plotted separately for each visit in Fig. 5 . During treatment, there was a significant inverse correlation between percent chenodiol and body weight at each visit. The reverse was noted for percent cholesterol saturation (Fig. 6 ).
The correlations between percent chenodiol and percent cholesterol saturation at each follow-up visit are presented in Table IV . There was a weak, but significant inverse correlation between percent chenodiol and percent saturation at base line (r = 0.14, P < 0.01). For the high-dose group, during follow- (Table IV) , the high-dose group showed a significant inverse correlation at month 3 between changes in percent chenodiol and percent cholesterol saturation (r = 0.130, P < 0.01), but not at month 12 nor month 24. The correlations for low-dose and placebo groups showed largely inverse relationships, but none were statistically significant.
Relation between biliary lipid composition andgallstone dissolution. In the low-dose group, only 42% had >70% chenodiol, and of these, 50% had unsaturated bile. Among the latter, none had complete dissolution, but 39% had partial dissolution. Among those with saturated bile, only 9% had complete dissolution, and only 17% showed partial or complete dissolution. Among those with <70% chenodiol, 80% had saturated bile, and of these only one patient had complete dissolution. For the placebo group, none reached 70% chenodiol; most were saturated, and complete dissolution was not observed.
The above data were analyzed by weighted least squares methods for contingency tables to determine whether >70% chenodiol or unsaturation were related to partial or complete dissolution. For the high-dose group, the effect of unsaturation was significant (P < 0.05) whereas percent chenodiol was not significant. Neither of these two effects were significant for the low-dose nor the placebo group.
Sample size in these analyses was limited (Table I) . However, examination ofthe individual patient data revealed that complete dissolution did not occur with chenodiol below 65 molar percent; and of the 15 patients achieving complete dissolution, 13 had a percent chenodiol >80%. Also, complete dissolution did not occur in any patient with an average cholesterol saturation > 125%, and two-thirds ofthose achieving complete dissolution had unsaturated bile.
Influence ofweight. An association was found between weight and percent chenodiol and percent cholesterol saturation in the high-dose group, as shown in Figs. 5 and 6. For higher body weights, the percent chenodiol in bile declined; also, lighter body weights were associated with a greater degree of unsaturation. For these measurements, the sex effect as well as the interaction effect between sex and weight are not significant. Thus, the two sex groups are combined.
Predicting average percent cholesterol saturation during treatment with chenodiol. Multiple regression analyses were conducted to explore the possibility of predicting the average percent cholesterol saturation during follow-up. The Based on weighted least squares contingency table analysis for the high-dose group, the effect of "unsaturation" was statistically significant (P < 0.05), but the effect of "Chenodiol > 70%" was not. Neither of these two effects were statistically significant for the low-dose nor the placebo group. * P of x2 on 1 df, or where appropriate, of Fisher's exact test.
entering that variable or the set in the model alone (model R2) or by considering its partial effects when added to the variables previously entered in the model (Extra R2). The regression model with all of the above variables explained 43% of the variation in the average percent saturation within the high-dose and the low-dose group and 26% within the placebo group. Within the high-dose group, all the variables of primary interest were significant (P < 0.05) either entered individually or entered additively; together they accounted for 30% of the variation in average percent saturation. Background variables were significant when entered as the first set of variables to be considered, but were not significant after controlling for the primary variables. None ofthe clinical, laboratory, or radiology factors reached statistical significance. Within the low-dose group, the primary variables other than sex were significant, either when entered individually or additively, but sex was not. The primary variables accounted for only 13% of the variation in average percent cholesterol saturation. The significance in the background variables was primarily due to the finding that those not married (n = 13) showed lower average percent cholesterol saturation (mean±SE: 97.34±5.14 for not married vs. 120.09±3.72 for those married). The significance in the laboratory tests was due to a moderate but significant correlation (r = 0.27) between SGPT and average percent cholesterol saturation. None of the clinical or radiologic variables were significant. Within the placebo group, the only significant factor was the percent saturation at base line.
Estimating the probability of gallstone dissolution. Based on the complete sample of patients in the high-dose group (n = 305), logistic regression models were previously developed (10) for the estimation ofthe probability ofgallstone dissolution by using the most predictive variables among those obtained at base line. Among patients on high dose in this study (n = 1 10), the following logistic models were obtained from the estimation of the probability of dissolution when average percent chenodiol and average percent cholesterol saturation during follow-up were added to these models. (The variable "Race" was not included because nonwhites were excluded from the bile study sample.) (a) Probability for complete dissolution = el/(1 The only variable that reached significance at the 0.05 level in the model for complete dissolution was average percent saturation; those in the model for partial or complete dissolution were sex and average percent saturation. The other variables had been significant in the analyses ofthe complete study sample, but did not reach significance levels in this study due to the reduction of sample size.
Based on the finding in the whole study that 13.5% ofpatients showed complete dissolution, the above models had an estimated sensitivity of 67% and a specificity of 77% in predicting complete Adverse effects ofchenodiol therapy. 
Discussion
Determinants ofbile saturation. This study (Figs. 1-4) showed that an intake of 750 mg/d chenodiol increased molar percent chenodiol in bile more than did 375 mg/d. At both doses, the percent of chenodiol during treatment was greater in women than in men. Percent chenodiol declined slightly by 24 mo from the peak month 3 values in both sexes and at both doses. Increases in percent chenodiol generally were associated with reductions in percent cholesterol saturation. In men, the reduction in percent saturation was essentially the same in both doses in the first 12 mo; however, at month 24, the low-dose group showed a rebound in percent saturation to the placebo level. In contrast, the response in women to the high dose was consistently greater than to low dose; in fact, on the average, the bile was unsaturated in women on the high dose. This was the only group in which, on the average, bile was unsaturated on chenodiol therapy. In both sexes on high dose, no rebound in percent saturation occurred at 24 mo as was observed for the low dose.
There might be several reasons for the rebound in percent saturation observed in both sexes on the low dose, but analyses which accounted for adherence, weight change, and exit from the study before 24 mo produced similar results, i.e., all showed the rebound effect. Thus, the rebound most likely is a biological effect. This may be related to the decrease in percent chenodiol in bile as the study progressed, which may have been due to a loss of feedback control on bile acid synthesis towards the end of the 2-yr period.
Previous studies (26, 27) have suggested that, during chenodiol therapy, the percent chenodiol in bile is a major factor associated with a decrease in bile saturation. In this study, difference in the percent cholesterol saturation between high-dose and low-dose groups support these findings (Figs. 1-4) . Furthermore, for both groups, there was an inverse correlation be- tween percent chenodiol and percent saturation; however, this was statistically significant only for the high-dose group (Table IV) . Weight was one of the factors, as observed in the major NCGS report (10) , to influence the rate of dissolution with chenodiol feeding. The inverse relationship ofweight to percent chenodiol (Fig. 5 ) and the direct relationship to percent cholesterol saturation (Fig. 6 ) probably can be explained by a positive correlation between body weight and synthesis (and biliary secretion) ofcholesterol (28) (29) (30) (31) . Since more cholesterol is secreted in bile in obese patients, a given amount of oral chenodiol should produce less reduction in percent cholesterol saturation, as shown previously (32, 33) . Unfortunately, because the NCGS was a fixed-dose trial, it was not possible to determine whether higher doses of chenodiol would override this effect of weight. Limited studies by other workers suggest that the obesity effect on percent saturation may be partially overcome by higher doses.
Determinants of gallstone dissolution. As reported in the major NCGS report (10) , gallstone dissolution occurred significantly more frequently on the high dose than on low dose. Since dissolution was almost nonexistent in the placebo group, an appreciable increase in percent chenodiol probably was necessary to induce dissolution. In accord, the present study showed that in the high-dose group very few patients achieved partial dissolution and none had complete dissolution when percent chenodiol was 70% (Table V) . The number of partial and complete dissolutions increased substantially when the level ofchenodiol exceeded 70%; and indeed, complete dissolution usually required >80% chenodiol in bile. However, since the majority of patients receiving this high level of chenodiol did not show dissolution, the percentage of chenodiol alone was not sufficient to explain rates of dissolution. In none of the groups was a significant correlation obtained between percent chenodiol alone and dissolution rate.
A more important factor contributing to dissolution appears to be percent saturation. In fact, the greatest likelihood of dissolution was for those who achieved not only 70% chenodiol in bile but also unsaturated bile. Therefore, it would appear that the factor most responsible for gallstone dissolution was not the amount of chenodiol per se, but the presence of a low level ofcholesterol saturation. From this study, it was not possible to determine whether desaturation ofbile (i.e., saturation <100%) is required for gallstone dissolution. Many patients showed at least partial dissolution in the presence of saturated bile. However, since the analysis was based on a maximum of only three collections, it is unlikely that these could precisely reflect the average degree of saturation over a 2-yr period. Thus, the measurement of bile composition from a single specimen during chenodiol therapy probably would not be an adequate predictor for gallstone dissolution in individual patients.
Determinants of adverse events. In relation to the adverse events of chenodiol therapy described (10), an association was observed only between percent during follow-up (<70% vs. >70%) and the incidence of SGPT elevations and diarrhea. Percent unsulfated lithocholic acid, however, was not associated with signs of hepatotoxicity. Such an association was demonstrated by Marks et al. (34) . In their study (34), however, percent unsulfated lithocholate was measured on all consenting patients, whereas in this paper, percent unsulfated lithocholate measurements were obtained only for those specimens with a percent total lithocholate .2%.
Limitations of the study. This study is based on the 326 white patients who had adequate bile specimens both at base line and at any follow-up visit. This is approximately one-third of the total NCGS study sample. Also, there were a greater percent men and less floating stones in the present study sample than in the total NCGS sample. Therefore, the results of this study cannot necessarily be generalized to the total NCGS study. Another limitation ofthe study was the small number of samples taken on each patient. The composition of bile is known to vary from one day to another, and many more measurements might have provided a better prediction ofgallstone dissolution.
